Drug Trial News

RSS

Norgine to develop and commercialize Tranzyme's ulimorelin ghrelin agonist

Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.

16 Jun 2010

NexMed's NexACT-based topical psoriasis treatment bioequivalent to Talconex

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced results from a pre-clinical study showing that calcipotriene 0.005% and betamethasone dipropionate 0.064%, when formulated with NexACT®, results in a topical treatment which shows bioequivalecy in efficacy to Talconex®, one of the leading topical treatments marketed for patients with mild to moderate psoriasis.

16 Jun 2010

Nymox near completion of new NX-1207 follow-up study for BPH

Nymox Pharmaceutical Corporation announced today that the Company is nearing completion of a new multi-center U.S. long-term follow-up study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH). Nymox expects to report final results and statistical analysis for the study in the next 1-2 weeks. The new study concerns assessment of the 48-60 month efficacy and benefits of a single treatment of NX-1207.

16 Jun 2010

New data from Phase 2a trial support further development of BMS-945429/ALD518 monoclonal antibody for RA

Bristol-Myers Squibb Company and Alder Biopharmaceuticals today announced that new data from a dose-ranging Phase 2a trial support further development of BMS-945429/ALD518, an investigational monoclonal antibody directed against interleukin-6 (IL-6), as a potential treatment for rheumatoid arthritis (RA). The Phase 2a data will be presented in a scientific session on June 18, 2010, at the Annual Congress of the European League against Rheumatism (EULAR).

16 Jun 2010

Results from ICH compliant Phase II study of MRX-4 presented at EAACI Congress

Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today the results from its ICH compliant Phase II study of MRX-4>th EAACI Congress in London. The study's principal investigators were Drs. Eric Bateman, Mary Bateman and Paul Potter.

16 Jun 2010

Final results from Visudyne Phase IIIb DENALI study presented at World Ophthalmology Congress

QLT Inc. today announced that final results from the Novartis-sponsored Phase IIIb DENALI study were presented on June 8, 2010 during the World Ophthalmology Congress in Berlin. DENALI was a 24-month randomized, double-masked, multicenter trial in patients with subfoveal choroidal neovascularization secondary to wet age-related macular degeneration (all lesion types).

16 Jun 2010

Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced the dosing of the first patient in a Phase I/II clinical trial of the doxorubicin conjugate of milatuzumab for the treatment of patients with relapsed multiple myeloma.

16 Jun 2010

Biogen Idec initiates enrollment in Phase II BG-12 combination trial for relapsing-remitting multiple sclerosis

Biogen Idec today announced enrollment of the first patient in a multicenter Phase II clinical trial designed to evaluate its investigational oral therapy BG-12 (dimethyl fumarate) in combination with commonly used first-line treatments in patients with relapsing-remitting multiple sclerosis (RRMS).

15 Jun 2010

Anacor's AN3365 novel systemic antibiotic achieves proof of concept

Anacor Pharmaceuticals today announced that a Joint Research Committee, composed of both GlaxoSmithKline (GSK) and Anacor employees, has determined that AN3365, a novel systemic antibiotic derived from Anacor's boron chemistry platform, has achieved proof of concept as defined under the collaboration agreement between GSK and Anacor.

15 Jun 2010

Positive clinical trial results for Anacor Pharmaceuticals' AN2728 announced

Anacor Pharmaceuticals today announced positive clinical trial results for its lead phosphodiesterase-4 inhibitor, AN2728, a novel topical anti-inflammatory compound derived from Anacor's boron chemistry platform. These results were obtained from a multi-center, Phase 2b, randomized, double-blind, dose-ranging, bilateral trial comparing AN2728 ointment, 0.5% and 2.0%, applied once or twice daily, to vehicle in 145 patients with mild-to-moderate plaque-type psoriasis.

15 Jun 2010

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

Researchers reported today that Soliris® (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc., may provide clinical benefits to patients with thrombotic microangiopathy (TMA) resulting from uncontrolled complement activation. TMA, the formation of blood clots in capillaries and small arteries, can lead to life-threatening damage in multiple organs including kidney failure, thrombocytopenia (abnormally low platelet count) and anemia.

15 Jun 2010

Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has immunized its first subject in a U.S. Phase I clinical trial to evaluate its SynCon™ H5N1 (avian) influenza DNA vaccine, VGX-3400X.

15 Jun 2010

Pieris commences PRS-050 anti-VEGF Anticalin Phase I clinical trial for cancer

Pieris AG announced today the initiation of a Phase I clinical trial in cancer patients for its lead program, PRS-050, an anti-VEGF Anticalin. The trial is an open-label, dose-escalating evaluation of the compound's safety and tolerability in patients with solid tumors. Conducted at three sites in Germany, the trial is underway and patients from the first cohort have been dosed.

15 Jun 2010

First patient treated in multicentre Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine for melanoma

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announces the enrolment and treatment of the first patient in its multicentre Phase I clinical trial of SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma. The trial will evaluate the safety and tolerability of SCIB1 in patients with late stage melanoma.

15 Jun 2010

Early administration of tranexamic acid to patients with severe bleeding injuries saves lives

If recently injured patients with serious bleeding were to receive a cheap, widely available and easily administered drug to help their blood to clot, tens of thousands of lives could be saved every year, according to a paper published on-line today by The Lancet.

15 Jun 2010

Aeterna Zentaris to present poster on AEZS-130 growth hormone secretagogue/ghrelin receptor agonist at 92nd ENDO

Aeterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrine therapy, today announced that a poster on its oral synthetic growth hormone secretagogue/ghrelin receptor agonist, AEZS-130, will be presented at the upcoming 92nd Annual Endocrine Society (ENDO) Meeting and Expo, which will be held June 19 through 22, 2010 at the San Diego Convention Center in San Diego, California.

15 Jun 2010

Micromet's blinatumomab demonstrates potential to change outcome for patients with ALL

Micromet, Inc. today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). Results of the analysis demonstrate that a prolonged hematologic relapse free survival was observed in patients treated with blinatumomab.

15 Jun 2010

Trubion announces Pfizer's decision to discontinue development of TRU-015 for RA

Trubion Pharmaceuticals, Inc. today announced Pfizer's decision to discontinue development of TRU-015 (PF-05212374), an investigational drug in Phase 2 evaluation for the treatment of rheumatoid arthritis (RA) developed under the companies' CD20 collaboration. However, Pfizer has confirmed that it will continue to develop SBI-087 (PF-05230895), Trubion's next-generation, humanized, subcutaneous CD20 RA product candidate also in Phase 2 clinical evaluation.

15 Jun 2010

Celator presents new data on CPX-351 liposome injection at European Hematology Association congress

Celator Pharmaceuticals today announced that new data from a preclinical leukemia study in mice demonstrate that its lead product, CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, alone or in combination with clofarabine or azacytidine can improve treatment outcomes compared to the combination of either agent with the conventional (unencapsulated) cytarabine:daunorubicin regimen.

15 Jun 2010

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

Genzyme Corporation announced today that its alemtuzumab for multiple sclerosis development program has been granted Fast Track status by the U.S. Food and Drug Administration (FDA). This designation covers patients with relapsing-remitting forms of the disease.

15 Jun 2010

Drug Trial News

Norgine to develop and commercialize Tranzyme's ulimorelin ghrelin agonist

NexMed's NexACT-based topical psoriasis treatment bioequivalent to Talconex

Nymox near completion of new NX-1207 follow-up study for BPH

New data from Phase 2a trial support further development of BMS-945429/ALD518 monoclonal antibody for RA

Results from ICH compliant Phase II study of MRX-4 presented at EAACI Congress

Final results from Visudyne Phase IIIb DENALI study presented at World Ophthalmology Congress

Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma

Biogen Idec initiates enrollment in Phase II BG-12 combination trial for relapsing-remitting multiple sclerosis

Anacor's AN3365 novel systemic antibiotic achieves proof of concept

Positive clinical trial results for Anacor Pharmaceuticals' AN2728 announced

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine

Pieris commences PRS-050 anti-VEGF Anticalin Phase I clinical trial for cancer

First patient treated in multicentre Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine for melanoma

Early administration of tranexamic acid to patients with severe bleeding injuries saves lives

Aeterna Zentaris to present poster on AEZS-130 growth hormone secretagogue/ghrelin receptor agonist at 92nd ENDO

Micromet's blinatumomab demonstrates potential to change outcome for patients with ALL

Trubion announces Pfizer's decision to discontinue development of TRU-015 for RA

Celator presents new data on CPX-351 liposome injection at European Hematology Association congress

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News